Administration of Sulfatide to Ameliorate Type I Diabetes in Non-Obese Diabetic Mice

Scandinavian Journal of Immunology

Volumn 79, Issue 4, 2014, Pages 260-266

  Rhost, S ^a   Lofbom L ^a   Mansson J E ^a   Lehuen, A ^b,c   Blomqvist, M ^a   Cardell, S L ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Hôpital Cochin/St Vincent de Paul ^*  (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; SULFATIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ARTICLE; AUTOIMMUNE DISEASE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; IMMUNOMODULATION; IMMUNOREACTIVITY; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

ANIMALS; ANTIGENS, CD1D; AUTOANTIBODIES; CYTOTOXICITY, IMMUNOLOGIC; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GALACTOSYLCERAMIDES; HUMANS; ISLETS OF LANGERHANS; MICE; MICE, INBRED NOD; NATURAL KILLER T-CELLS; SULFOGLYCOSPHINGOLIPIDS;

EID: 84897840011     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12157     Document Type: Article

References (45)

1. Jayasimhan A, Mansour KP, Slattery RM. Advances in our understanding of the pathophysiology of Type 1 diabetes: lessons from the NOD mouse. Clin Sci (Lond) 2014;126:1-18.
2. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005;23:447-85.
3. Lehuen A, Diana J, Zaccone P, Cooke A. Immune cell crosstalk in type 1 diabetes. Nat Rev Immunol 2010;10:501-13.
4. Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 2004;114:1379-88.
5. Falcone M, Yeung B, Tucker L, Rodriguez E, Sarvetnick N. A defect in interleukin 12-induced activation and interferon gamma secretion of peripheral natural killer T cells in nonobese diabetic mice suggests new pathogenic mechanisms for insulin-dependent diabetes mellitus. J Exp Med 1999;190:963-72.
6. Godfrey DI, Kinder SJ, Silvera P, Baxter AG. Flow cytometric study of T cell development in NOD mice reveals a deficiency in alphabetaTCR+CDR-CD8- thymocytes. J Autoimmun 1997;10:279-85.
7. Gombert JM, Herbelin A, Tancrede-Bohin E, Dy M, Carnaud C, Bach JF. Early quantitative and functional deficiency of NK1+-like thymocytes in the NOD mouse. Eur J Immunol 1996;26:2989-98.
8. Hammond KJ, Poulton LD, Palmisano LJ, Silveira PA, Godfrey DI, Baxter AG. alpha/beta-T cell receptor (TCR)+CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J Exp Med 1998;187:1047-56.
9. Jordan MA, Fletcher J, Baxter AG. Genetic control of NKT cell numbers. Immunol Cell Biol 2004;82:276-84.
10. Parekh VV, Singh AK, Wilson MT et al. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids. J Immunol 2004;173:3693-706.
11. Poulton LD, Smyth MJ, Hawke CG et al. Cytometric and functional analyses of NK and NKT cell deficiencies in NOD mice. Int Immunol 2001;13:887-96.
12. Shi FD, Flodstrom M, Balasa B et al. Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse. Proc Natl Acad Sci U S A 2001;98:6777-82.
13. Rhost S, Sedimbi S, Kadri N, Cardell SL. Immunomodulatory type II natural killer T lymphocytes in health and disease. Scand J Immunol 2012;76:246-55.
14. Blomqvist M, Rhost S, Teneberg S et al. Multiple tissue-specific isoforms of sulfatide activate CD1d-restricted type II NKT cells. Eur J Immunol 2009;39:1726-35.
15. Jahng A, Maricic I, Aguilera C, Cardell S, Halder RC, Kumar V. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J Exp Med 2004;199:947-57.
16. Patel O, Pellicci DG, Gras S et al. Recognition of CD1d-sulfatide mediated by a type II natural killer T cell antigen receptor. Nat Immunol 2012;13:857-63.
17. Buschard K, Josefsen K, Hansen SV et al. Sulphatide in islets of Langerhans and in organs affected in diabetic late complications: a study in human and animal tissue. Diabetologia 1994;37:1000-6.
18. Ishizuka I. Chemistry and functional distribution of sulfoglycolipids. Prog Lipid Res 1997;36:245-319.
19. Shamshiev A, Donda A, Carena I, Mori L, Kappos L, De Libero G. Self glycolipids as T cell autoantigens. Eur J Immunol 1999;29:1667-75.
20. Ambrosino E, Terabe M, Halder RC et al. Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis. J Immunol 2007;179:5126-36.
21. Arrenberg P, Maricic I, Kumar V. Sulfatide-mediated activation of type II natural killer T cells prevents hepatic ischemic reperfusion injury in mice. Gastroenterology 2011;140:646-55.
22. Halder RC, Aguilera C, Maricic I, Kumar V. Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease. J Clin Invest 2007;117:2302-12.
23. Sundell IB, Halder R, Zhang M, Maricic I, Koka PS, Kumar V. Sulfatide administration leads to inhibition of HIV-1 replication and enhanced hematopoeisis. J Stem Cells 2010;5:33-42.
24. Kwiecinski J, Rhost S, Lofbom L et al. Sulfatide attenuates experimental Staphylococcal aureus sepsis through a CD1d dependent pathway. Infect Immun 2013; 81:1114-20.
25. Andersson K, Buschard K, Fredman P et al. Patients with insulin-dependent diabetes but not those with non-insulin-dependent diabetes have anti-sulfatide antibodies as determined with a new ELISA assay. Autoimmunity 2002;35:463-8.
26. Buschard K, Blomqvist M, Osterbye T, Fredman P. Involvement of sulfatide in beta cells and type 1 and type 2 diabetes. Diabetologia 2005;48:1957-62.
27. Buschard K, Hoy M, Bokvist K et al. Sulfatide controls insulin secretion by modulation of ATP-sensitive K(+)-channel activity and Ca(2+)-dependent exocytosis in rat pancreatic beta-cells. Diabetes 2002;51:2514-21.
28. Fredman P, Mansson JE, Rynmark BM et al. The glycosphingolipid sulfatide in the islets of Langerhans in rat pancreas is processed through recycling: possible involvement in insulin trafficking. Glycobiology 2000;10:39-50.
29. Osterbye T, Jorgensen KH, Fredman P et al. Sulfatide promotes the folding of proinsulin, preserves insulin crystals, and mediates its monomerization. Glycobiology 2001;11:473-9.
30. Buschard K, Josefsen K, Horn T, Fredman P. Sulphatide and sulphatide antibodies in insulin-dependent diabetes mellitus. Lancet 1993;342:840.
31. Hussain S, Wagner M, Ly D, Delovitch TL. Role of regulatory invariant CD1d-restricted natural killer T cells in protection against type 1 diabetes. Immunol Res 2005;31:177-88.
32. Wilson SB, Delovitch TL. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat Rev Immunol 2003;3:211-22.
33. Buschard K, Hanspers K, Fredman P, Reich EP. Treatment with sulfatide or its precursor, galactosylceramide, prevents diabetes in NOD mice. Autoimmunity 2001;34:9-17.
34. Wang B, Geng YB, Wang CR. CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J Exp Med 2001;194:313-20.
35. Fredman P, Mattsson L, Andersson K et al. Characterization of the binding epitope of a monoclonal antibody to sulphatide. Biochem J 1988;251:17-22.
36. Blomqvist M, Carrier M, Andrews T et al. In vivo administration of the C16:0 fatty acid isoform of sulfatide increases pancreatic sulfatide and enhances glucose-stimulated insulin secretion in Zucker fatty (fa/fa) rats. Diabetes Metab Res Rev 2005;21:158-66.
37. Rosengren B, Fredman P, Mansson JE, Svennerholm L. Lysosulfatide (galactosylsphingosine-3-O-sulfate) from metachromatic leukodystrophy and normal human brain. J Neurochem 1989;52:1035-41.
38. Sireci G, Russo D, Dieli F et al. Immunoregulatory role of Jalpha281 T cells in aged mice developing lupus-like nephritis. Eur J Immunol 2007;37:425-33.
39. Wermeling F, Lind SM, Jordo ED, Cardell SL, Karlsson MC. Invariant NKT cells limit activation of autoreactive CD1d-positive B cells. J Exp Med 2010;207:943-52.
40. Mevorach D, Zhou JL, Song X, Elkon KB. Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med 1998;188:387-92.
41. Yang SH, Lee JP, Jang HR et al. Sulfatide-reactive natural killer T cells abrogate ischemia-reperfusion injury. J Am Soc Nephrol 2011;22:1305-14.
42. Agren LC, Ekman L, Lowenadler B, Lycke NY. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J Immunol 1997;158:3936-46.
43. Zajonc DM, Maricic I, Wu D et al. Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity. J Exp Med 2005;202:1517-26.
44. Shoda LK, Young DL, Ramanujan S et al. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 2005;23:115-26.
45. Subramanian L, Blumenfeld H, Tohn R et al. NKT cells stimulated by long fatty acyl chain sulfatides significantly reduces the incidence of type 1 diabetes in nonobese diabetic mice. PLoS One 2012;7:e37771.